Outpacing
cancer starts with early detection
Detecting cancer early can make a world of difference. Freenome is setting a new pace for early cancer detection by combining the latest in science and artificial intelligence, with the ease of a standard blood draw.
Outpacing
cancer starts with early detection
Detecting cancer early can make a world of difference. Freenome is setting a new pace for early cancer detection by combining the latest in science and artificial intelligence, with the ease of a standard blood draw.
A novel approach to screening
Freenome’s intelligent screening platform uses multiomics technology to detect cancer in its earliest, most treatable stages.
Powered by a rigorous clinical program
Our research programs drive discovery, development, and validation of our early cancer detection tests.
Multi-disciplinary leadership with purpose
We bring together passionate creators and ambitious builders. Together, we are relentless in pushing for what’s possible in early cancer detection.
“It was clear that to make a real dent in ending cancer, we needed to improve the entire concept of early detection. That was the motivation to start Freenome.”
Riley Ennis
Co-founder and Chief Product Officer